Hyperbaric Oxygen Therapy Does Not Have a Negative Impact on Bone Signaling Pathways in Humans

Zaida Salmón-González 1, Javier Anchuelo 2, Juan C. Borregán 3, Alvaro del Real 1*, Carolina Sañudo 1, Maria Teresa García-Unzueta 4, José A. Riancho 1, Carmen Valero 1*

1 Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, 39008 Santander, Spain; zaida.salmon@scsalud.es (Z.S.-G.); alvarodel.real92@gmail.com (A.d.R.); carolinasanudo@gmail.com (C.S.); jose.riancho@unican.es (J.A.R.)
2 Service of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain; javier Tomas.anchuelo@scsalud.es
3 Service of Intensive Care, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain; juan carlos.rborregan@scsalud.es
4 Service of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 Santander, Spain; m teresa.garciau@scsalud.es
* Correspondence: mirvdc@humv.es

Abstract: Introduction: Oxygen is emerging as an important factor in the local regulation of bone remodeling. Some preclinical data suggest that hyperoxia may have deleterious effects on bone cells. However, its clinical relevance is unclear. Hence, we studied the effect of hyperbaric oxygen therapy (HBOT) on serum biomarkers reflecting the status of the Wnt and receptor activator of NF-κB ligand (RANKL) pathways, two core pathways for bone homeostasis. Materials and methods: This was a prospective study of 20 patients undergoing HBOT (mean age 58 yrs., range 35–82 yrs.) because of complications of radiotherapy or chronic anal fissure. Patients were subjected to HBOT (100% oxygen; 2.4 atmospheres absolute for 90 min). The average number of HBOT sessions was 20 ± 5 (range 8–31). Serum hypoxia-inducible factor 1-α (HIF1-α), osteoprotegerin (OPG), RANKL, and the Wnt inhibitors sclerostin and dickkopf-1 (DKK1) were measured at baseline and after HBOT by using specific immunoassays. Results: HIF1-α in eight patients with measurable serum levels increased from 0.084 (0.098) ng/mL at baseline to 0.146 (0.130) ng/mL after HBOT (p = 0.028). However, HBOT did not induce any significant changes in the serum levels of OPG, RANKL, sclerostin or DKK1. This was independent of the patients’ diagnosis, either neoplasia or benign. Conclusion: Despite the potential concerns about hyperoxia, we found no evidence that HBOT has any detrimental effect on bone homeostasis.

Keywords: hyperbaric oxygen therapy; osteoprotegerin; RANKL; sclerostin; DKK1; HIF-1α

1. Introduction

Bone tissue is continuously remodeled by the concerted action of bone-resorbing osteoclasts and bone-forming osteoblasts. The Wnt and RANKL pathways are master regulators of bone remodeling [1]. Wnt ligands are expressed by a variety of skeletal and non-skeletal cell types. Within the bone microenvironment, they are critical factors promoting the proliferation and differentiation of mesenchymal stem cells into the bone-forming osteoblasts [2]. The activity of the Wnt pathway within bone tissue is critically determined by the local levels of sclerostin and DKK1 [3,4]. These two soluble factors are secreted by osteocytes and other bone cells and prevent the activation of Wnt receptors by Wnt ligands [5]. The central role of these factors is revealed by the anabolic effect and increase in bone mass observed after therapy with neutralizing antibodies against sclerostin and DKK1, both in experimental models and in clinical practice [6].

Osteoclasts, the cells responsible for bone resorption, originate from hematopoietic precursors of the monocyte lineage. The binding of RANKL to RANK receptors present...
in osteoclast precursors is critical for their differentiation toward mature osteoclasts, as
revealed by the profound inhibition of bone resorption induced by anti-RANKL antibodies,
which are a well-established therapy for osteoporosis [7]. Osteoprotegerin (OPG) is an
endoogenous soluble decoy receptor for RANKL that prevents the binding of RANKL to its
receptor RANK. Thus, the RANKL/OPG ratio in the bone microenvironment modulates
osteoclast formation and consequently bone resorption.

Oxygen is critical for maintaining cell function, including that of bone cells [8]. In
some experimental models, hypoxia stimulates the activity of bone-resorbing osteoclasts
and inhibits the activity of bone-forming osteoblasts [9,10]. In contrast, hypoxia may
have opposite effects [11,12]. Hyperbaric oxygen therapy (HBOT) has anti-inflammatory
effects [13], and it has been shown to be useful in the treatment of radiation-therapy-related
complications (such as hemorrhagic cystitis or proctitis) and also in some bone disorders
such as osteomyelitis [14], bisphosphonate-related osteonecrosis of the jaw [15], femoral
head necrosis [16], and transient osteoporosis [17]. HBOT increases the partial pressure
of oxygen in plasma and in tissues. However, the effects of HBOT on bone cells in vivo
is unclear. HBOT could have either beneficial effects on bone, regulating the expression
of hypoxia-inducible factor 1α (HIF-1α) [18], or detrimental effects related to oxidative
damage [19]. To clarify this issue, we studied the effect of HBOT on serum levels of
biomarkers of the Wnt and RANKL/OPG pathways.

2. Materials and Methods

This was a prospective study of 20 patients subjected to HBOT. The mean age was
58 yrs. (range 35–82 yrs.), with 40% men and 60% women. Ten of them had a history of neo-
plasms, without bone metastases, and HBOT was indicated by the clinicians in charge due
to complications of radiation therapy (proctitis 50%, cystitis 30%, and radionecrosis 20%;
average total radiotherapy dose 50.7 Gy). Ten other patients without cancer underwent
HBOT for chronic anal fissure that did not improve with conventional therapy.

HBOT was applied with a hyperbaric chamber (Galeazzi, Livorno, Italy), with 100%
oxygen, at 2.4 atmospheres for 90 min while breathing through an oral-nasal mask, 5 times
a week, with an average of 20 ± 5 sessions. The study protocol was approved by the
institutional review board, and all patients provided written informed consent.

Baseline blood samples were obtained before starting the first HBOT session, and
the second sample was extracted 30 min after the end of the last HBOT session. Serum
aliquots were stored at −80 °C until analysis. Serum concentrations of HIF1-α, OPG,
RANKL, sclerostin, and DKK1 were analyzed with immunoassays kits according to the
manufacturers’ instructions. Both samples from each patient were analyzed within the
same assay run. HIF-1α was measured by ELISA (Sigma-Aldrich, Saint Louis, MO, USA).
The lower limit of detection was 61 pg/mL; the within-assay coefficient of variation (CV)
was <10%. OPG was measured by ELISA (Sigma-Aldrich, Saint Louis, MO, USA). The
lower limit of detection was 1 pg/mL; the intra-assay CV was <10%. RANKL was measured
by ELISA (Biovendor). The lower limit of detection was 0.4 pmol/L; the intra-assay CV was <10%. DKK1 was measured by ELISA (Sigma-Aldrich). The
lower limit of detection was 0.1 ng/mL; the intra-assay CV was <10%. Sclerostin was
measured by ELISA (Tecnomedical, San Diego, CA, USA). Due to sample limitations,
it was measured only in 12 patients. The lower limit of detection was 0.01 ng/mL; the
intra-assay CV was <10%. C-reactive protein was quantified by an immunonephelometric
assay (Behring Nephelometer Analyzer II, Behring Diagnostics, Marburg, Germany) using
the ultrasensitive method. Analytical sensitivity was 0.03 mg/dL; the intra-assay CV was
<3%. The normal reference range is 0.01–0.3 mg/dL.

Statistical Analysis

Medians and interquartile ranges were used as the summary parameters. The Wilcoxon
test for paired data was used to compare the baseline and post-HBOT serum biomarker
levels using SPSS 15.0 software (IBM, Chicago, IL, USA). A p-value of <0.05 was considered statistically significant.

3. Results

The main clinical characteristics of the studied patients are listed in Table 1. The average number of HBOT sessions was 20 ± 5 (range 8–31), similar in both groups (23 ± 5 in neoplasms and 18 ± 4 in anal fissure).

Table 1. Main clinical features of the study population.

|                        | 58 (15) |
|------------------------|---------|
| **Age (yrs.), Mean (SD)** |         |
| **Sex male, n (%)**    | 8 (40%) |
| **Physical activity, n (%)** |       |
| -Sedentary (<2 h/week) | 2 (10%) |
| -Moderate (2–4 h/week) | 14 (70%)|
| -Vigorous (>4 h/week)  | 4 (20%) |
| **Alcohol consumption, n (%)** |        |
| 4 (20%)                |         |
| **Smoker habit, n (%)** |         |
| 2 (10%)                |         |
| **Charlson comorbidity index, n (%)** |     |
| -0                     | 5 (25%) |
| -1–2                   | 11 (55%)|
| -3–4                   | 3 (15%) |
| ->4                    | 1 (5%)  |
| **HBOT indication, n (%)** |       |
| -Anal fissure          | 10 (50%)|
| -Proctitis             | 5 (25%) |
| -Cystitis              | 2 (10%) |
| -Radionecrosis         | 3 (15%) |
| **Tumor type, n (%)**  |         |
| -Adenocarcinoma rectum/colon | 3 (30%)|
| -Carcinoma head and neck | 3 (30%)|
| -Carcinoma prostate    | 2 (20%) |
| -Adenocarcinoma gynecological | 2 (20%)|

Charlson comorbididy index [20].

HIF-1α serum levels were below the limit of detection in 12 patients. Among those with detectable levels, HIF-1α increased by 63% with HBOT, from 0.084 (0.098) ng/mL at baseline to 0.146 (0.130) ng/mL after HBOT (p = 0.028) (Figure 1).

No changes were found in the levels of C-reactive protein: 0.31 (0.62) mg/dL in T0 and 0.21 (0.90) mg/dL in T1 (p = 0.37)

There were no significant changes after HBOT in serum OPG, RANKL, sclerostin, or DKK1 levels in comparison with baseline levels (Table 2).
Table 2. Levels of bone biomarkers before and after HBOT.

| Bone Biomarkers | Baseline (n = 20) | After HBOT (n = 20) | p-Value |
|-----------------|-------------------|---------------------|---------|
| OPG pg/mL       | 154 (62)          | 165 (64)            | 0.73    |
| RANKL pmol/L    | 352 (249)         | 334 (228)           | 0.50    |
| Sclerostin * ng/mL | 0.87 (1.38)     | 0.73 (0.67)         | 0.11    |
| DKK1 ng/mL      | 2.88 (6.22)       | 3.15 (8.01)         | 0.39    |

Median (and interquartile range). OPG: osteoprotegerin; RANKL: receptor activator for nuclear factor kappa B ligand; DKK1: dickkopf-1. * Sclerostin levels were measured only in 12 patients.

No HBOT-induced differences in bone biomarkers were observed either when patients were stratified according to diagnosis (Tables 3 and 4).

Table 3. Bone biomarkers in patients with neoplasms.

| Bone Biomarkers | Baseline (n = 10) | After HBOT (n = 10) | p-Value |
|-----------------|-------------------|---------------------|---------|
| OPG pg/mL       | 155 (78)          | 173 (97)            | 0.24    |
| RANKL pmol/L    | 357 (202)         | 343 (262)           | 0.50    |
| Sclerostin * ng/mL | 1.16 (1.18)    | 0.65 (1.28)         | 0.18    |
| DKK1 ng/mL      | 1.62 (3.03)       | 1.81 (2.94)         | 0.87    |

Median (and interquartile range). OPG: osteoprotegerin; RANKL: receptor activator for nuclear factor kappa B ligand; DKK1: dickkopf-1. * Sclerostin levels were measured only in 6 patients.

Table 4. Bone biomarkers in patients with anal fissure.

| Bone Biomarkers | Baseline (n = 10) | After HBOT (n = 10) | p-Value |
|-----------------|-------------------|---------------------|---------|
| OPG pg/mL       | 148 (79)          | 159 (82)            | 0.12    |
| RANKL pmol/L    | 332 (431)         | 323 (252)           | 0.47    |
| Sclerostin * ng/mL | 0.57 (1.58)     | 0.83 (1.02)         | 0.11    |
| DKK1 ng/mL      | 3.35 (8.98)       | 3.44 (8.12)         | 0.33    |

Median (and interquartile range). OPG: osteoprotegerin; RANKL: receptor activator for nuclear factor kappa B ligand; DKK1: dickkopf-1. * Sclerostin levels were measured only in 6 patients.

4. Discussion

The effects of oxygen on body homeostasis are mediated in part by HIFs. HIFs are heterodimeric proteins composed of a HIF-α and a HIF-β subunit. HIF-1α has an important role in the regulation of genes related to bone metabolism [21]. In normoxia (>5%), prolyl hydroxylase domain (Phd) proteins hydroxylate proline residues in HIF-α subunits. In hypoxia, HIF-α hydroxylation by Phd is prevented, and HIF-α accumulates, associates with HIF-β, and induces the expression of target genes, increasing osteoclast activity. The effect on osteoblast activity is more complex, because it may be reduced by HIFs, but may be indirectly stimulated by the induction of vascular endothelial growth factor (VEGF) [22]. The expression of HIF in hyperoxia-associated situations seems to be rather complex, too. A study in vivo with human peripheral blood mononuclear cells showed...
that the return to normoxia after 1 hour of exposure with mild or high oxygen (30% and 100% O₂, respectively) resulted in a hypoxia-like response, characterized by increased HIF-1α. However, the exposure to high oxygen concentrations did not result in changes in HIF-1α [19] but to an oxidative stress response that could be detrimental to bone due to increased reactive oxygen species (ROS) and oxidative damage [23–25].

In this study, we found increased HIF-1α levels after HBOT, but this did not seem to impact the major drivers of osteoblast and osteoclast differentiation. The OPG/RANK/RANKL system regulates osteoclastogenesis. OPG, the soluble decoy receptor for RANKL, inhibits RANKL binding to RANK and prevents bone resorption [26]. Hypoxia and hyperoxia could modulate the RANKL/OPG ratio [27,28]. However, we did not find any HBOT-induced changes in serum OPG or RANKL levels. These results are consistent in part with those of a previous study of patients with femoral head necrosis, which found that OPG increases with HBOT, whereas RANKL does not change [29]. However, it is hard to know whether OPG changes were due to oxygen therapy itself or to the potential modifications of the bone lesion.

The Wnt pathway is a master regulator of osteoblastogenesis [30]. Oxygen levels influence the functioning of this signaling pathway in experimental models [31]. Sclerostin, the product of the SOST gene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes and tends to decrease bone formation [32]. Hypoxia decreases SOST expression and consequently increases Wnt signaling in osteoblasts [33]. Thus, although these effects have not been confirmed in all studies [34,35], hypoxia could result in increased bone formation, whereas hyperoxia could decrease it. However, the results in different experimental systems are rather contradictory. In fact, it has been reported that HBOT increases the osteogenic differentiation of mesenchymal stem cells in vitro [12], whereas in an animal model, HBOT appeared to protect from the osteoporosis induced by hind limb unloading through decreased SOST expression [36]. DKK1 is another important modulator of the Wnt pathway [37]. Hypoxia seems to modulate the expression of DKK1 [38], but the effects of hyperoxia have not been studied. In our study, we did not find any evidence of increased levels of sclerostin or DKK1 in patients who were exposed to HBOT. Overall, these results are in line with the absence of significant changes in bone turnover markers in patients exposed to HBOT, as well as with the limited effects of HBOT on bone samples ex vivo [35].

HBOT may have anti-inflammatory effects [39,40], which may secondarily influence bone metabolism [41]. The lack of effects of HBOT on CRP levels in this study must be interpreted, taking into consideration the fact that our patients already had low CRP levels at baseline, consistent with the absence of marked active inflammation.

Our study had several limitations, including a moderate sample size, which resulted in a relatively high type II error and limited the statistical power. We also consider a limitation the absence of direct measurements within the bone microenvironment medium. HIF-1α is a rather labile compound, which may have contributed to the fact that it was unmeasurable in some patients. In addition, since we did not measure other mediators of the response to oxygen levels (i.e., Phd, HIF-2), we cannot exclude other effects of HBOT. In addition, importantly, our results cannot be necessarily generalized to other conditions and HBOT schedules. Nevertheless, our results about serum biomarkers are reassuring. We did not find any evidence of a deleterious effect of HBOT, as applied in this study, on the activity of skeletal cells.

Author Contributions: Conceptualization, J.A.R., Z.S.-G., C.V. and J.A.; data curation, C.V.; investigation, C.V., J.A.R. and Z.S.-G.; methodology, Z.S.-G., C.S. and A.d.R.; project administration, J.A.R., C.V. and Z.S.-G.; resources, C.S., M.T.G.-U., A.d.R., J.C.B.; software, Z.S.-G.; supervision, C.V., J.A.R.; validation, J.A.R. and C.V.; writing—original draft preparation, Z.S.-G.; writing—review and editing, C.V. and J.A.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Instituto de Investigación Sanitaria Valdecilla (IDIVAL).
References

1. Kenkre, J.S.; Bassett, J. The bone remodelling cycle. *Annu. Clin. Biochem.* 2018, 55, 308–327. [CrossRef]
2. Kobayashi, Y.; Uehara, S.; Udagawa, N.; Takahashi, J.N. Regulation of bone metabolism by Wnt signals. *J. Biochem.* 2016, 159, 387–392. [CrossRef] [PubMed]
3. Maeda, K.; Kobayashi, Y.; Koide, M.; Uehara, S.; Okamoto, M.; Ishihara, A.; Kayahara, T.; Saito, M.; Marumo, K. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. *Int. J. Mol. Sci.* 2019, 20, 5525. [CrossRef] [PubMed]
4. Delgado-Calle, J.; Sato, A.Y.; Bellido, T. Role and mechanism of action of sclerostin in bone. *Bone* 2017, 96, 29–37. [CrossRef] [PubMed]
5. Robling, A.G.; Bonewald, L.F. The Osteocyte: New Insights. *Annu. Rev. Physiol.* 2021, 83, 1–28. [CrossRef] [PubMed]
6. Fabre, S.; Funck-Brentano, T.; Cohen-Solal, M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. *Clin. Cases Miner. Bone Metab.* 2020, 19, 209–216. [CrossRef] [PubMed]
7. Matsumoto, T.; Endo, I. RANKL as a target for the treatment of osteoporosis. *J. Bone Miner. Metab.* 2021, 39, 91–105. [CrossRef]
8. Watson, E.C.; Adams, R.H. Biology of Bone: The Vasculature of the Skeletal System. *Cell Biochem. Funct.* 2020, 38, 3–9. [CrossRef] [PubMed]
9. Arnett, T.R. Acidosis, hypoxia and bone. *Arch. Biochem. Biophys.* 2010, 497, 22–32. [CrossRef] [PubMed]
10. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic Dis.* 1987, 40, 373–383. [CrossRef]
11. Fratantonio, D.; Virgili, F.; Zucchi, G.; Giacon, T.A.; Camporesi, M.; Bosco, G. Evidence-Supported HBO Therapy in Femoral Head Necrosis: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 2920. [CrossRef] [PubMed]
12. Paderno, E.; Zanon, V.; Giacon, T.A.; Camporesi, M.; Bosco, G. Evidence-Supported HBO Therapy in Femoral Head Necrosis: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 2920. [CrossRef] [PubMed]
13. Ortega, M.A.; Fraile-Martinez, O.; Garcí-Montero, C.; Callejón-Peláez, E.; Sáez, M.A.; Álvarez-Mon, M.A.; García-Honduvilla, N.; Monserrat, J.; Álvarez-Mon, M.; Buján, J.; et al. General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities. *Medicina* 2021, 57, 684. [CrossRef] [PubMed]
14. Memar, M.Y.; Yekani, M.; Alizadeh, N.; Baghi, H.B. Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections. *Biom. Pharmaco.* 2019, 109, 440–447. [CrossRef] [PubMed]
15. Ceponis, P.; Keilmann, C.; Guerry, C.; Freiberger, J. Hyperbaric oxygen therapy and osteonecrosis. *Oral Dis.* 2017, 23, 141–151. [CrossRef] [PubMed]
16. Paderno, E.; Zanon, V.; Giacon, T.A.; Enrico, T.L.B.; Camporesi, M.; Bosco, G. Evidence-Supported HBO Therapy in Femoral Head Necrosis: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 2888. [CrossRef]
17. Ververidis, A.N.; Paraskevopoulos, K.; Keskinis, A.; Ververidis, N.A.; Moustafà, R.M.; Tilkéridis, K. Bone marrow edema syndrome/ transient osteoporosis of the hip joint and management with the utilization of hyperbaric oxygen therapy. *J. Orthop. Res.* 2020, 22, 29–32. [CrossRef] [PubMed]
18. Hannah, S.S.; McFadden, S.; McNeilly, A.; McClean, C. “Take My Bone Away?” Hypoxia and bone: A narrative review. *J. Cell. Physiol.* 2021, 236, 721–740. [CrossRef]
19. Fratantonio, D.; Virgili, F.; Zucchi, G.; Giacon, T.A.; Enrico, T.L.B.; Camporesi, M.; Bosco, G. Evidence-Supported HBO Therapy in Femoral Head Necrosis: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 2888. [CrossRef]
20. Schipani, E.; Maes, C.; Carmeliet, G.; Semenza, G.L. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. *J. Bone Miner. Res.* 2009, 24, 1347–1353. [CrossRef] [PubMed]
21. Charlsont, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic Dis.* 1987, 40, 373–383. [CrossRef]
22. Agidigbi, T.S.; Chaekyun Kim, C. Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases. *Int. J. Mol. Sci.* 2019, 20, 3576. [CrossRef] [PubMed]
23. Callaway, D.A.; Jiang, J.X. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. *J. Bone Miner. Metab.* 2015, 33, 359–370. [CrossRef] [PubMed]
24. Vlada Domazetovic, V.; Marcucci, G.; Iantomas, T.; Brandi, M.L.; Vincenzini, M.T. Oxidative stress in bone remodeling: Role of antioxidants. *Clin. Cases Miner. Bone Metab.* 2017, 14, 209–216. [CrossRef] [PubMed]

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Cantabria Drug Research Ethics Committee with file number 2015.220.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study is private.

Conflicts of Interest: The authors declare no conflict of interest.
26. Yasuda, H. Discovery of the RANKL/RANK/OPG system. *J. Bone Miner. Metab.* 2021, 39, 2–11. [CrossRef] [PubMed]

27. Yu, X.; Xiao, C.; Du, Y.; Liu, S.; Dum, Y.; Li, S. Effect of hypoxia on the expression of RANKL/OPG in human periodontal ligament cells in vitro. *Int. J. Clin. Exp. Pathol.* 2015, 8, 12929–12935. [PubMed]

28. Silva, M.L.; Tasso, L.; Azambuja, A.A.; Figueiredo, M.A.; Gonçalves Salum, F.G.; Duval da Silva, V.; Cherubini, K. Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis. *Clin. Oral Investig.* 2017, 21, 199–210. [CrossRef] [PubMed]

29. Vezzani, G.; Quartsesan, S.; Cancellara, P.; Camporesi, E.; Mangar, D.; Bernasek, T.; Dalvi, P.; Yang, Z.; Paoli, A.; Rizzato, A.; et al. Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients. *J. Enzym. Inhib. Med. Chem.* 2017, 32, 707–711. [CrossRef]

30. Tang, C.-Y.; Wu, M.; Zhao, D.; Edwards, D.; McVicar, A.; Luo, Y.; Zhu, G.; Wang, Y.; Zhou, H.-D.; Chen, W.; et al. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. *PLoS Genet.* 2021, 17, e1009233. [CrossRef] [PubMed]

31. Stegen, S.; Stockmans, I.; Moermans, K.; Thienpont, B.; Maxwell, P.H.; Carmeliet, P.; Carmeliet, G. Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. *Nat. Commun.* 2018, 9, 2557. [CrossRef]

32. Weivoda, M.M.; Youssef, S.J.; Oursler, M.J. Sclerostin expression and functions beyond the osteocyte. *Bone* 2017, 96, 45–50. [CrossRef]

33. Genetos, D.C.; Toupadakis, C.A.; Raheja, L.F.; Wong, A.; Papanicolaou, S.E.; Fyhrie, D.F.; Lofts, G.G.; Yellowley, C.E. Hypoxia Decreases Sclerostin Expression and Increases Wnt Signaling in Osteoblasts. *J. Cell Biochem.* 2010, 110, 457–467. [CrossRef]

34. Janjić, K.; Cvikl, B.; Kurzmann, C.; Moritz, A.; Agis, H. Do hypoxia and L-mimosine modulate sclerostin and dickkopf-1 production in human dental pulp-derived cells? Insights from monolayer, spheroid and tooth slice cultures. *BMC Oral Health* 2018, 18, 36. [CrossRef] [PubMed]

35. Salmón-González, Z.; Anchuelo, J.; Borregán, J.C.; Real, A.; Sañudo, C.; García, C.; Pérez, M.I.; Riancho, J.A.; Valero, C. Influencia del oxígeno a alta concentración en cámara hiperbárica sobre el metabolismo óseo. *Rev. Osteoporos. Metab. Miner.* 2020, 12, 28–31. [CrossRef]

36. Takemura, A.; Paola, P.D.; Egawa, T.; Teshigawara, R.; Hayashi, T.; Ishihara, A. Effects of mild hyperbaric oxygen on osteoporosis induced by hindlimb unloading in rats. *J. Bone Miner. Metab.* 2020, 38, 631–638. [CrossRef] [PubMed]

37. Schupbach, D.; Comeau-Gauthier, M.; Harvey, E.; Merle, G. Wnt modulation in bone healing. *Bone* 2020, 138, 115491. [CrossRef] [PubMed]

38. Xu, Y.; Guo, J.; Liu, J.; Xie, Y.; Li, X.; Jiang, H.; Wang, J.; Peng, Z.; Wang, J.; Wang, S.; et al. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple mieloma. *Oncogene* 2021, 40, 1231–1241. [CrossRef] [PubMed]

39. Mulawarmanti, D.; Parishini, K.; Widyastruti, W. The Impact of Hyperbaric Oxygen Therapy on Serum C-Reactive Protein Levels, Osteoprotegerin Expression, and Osteoclast Numbers in Induced-Periodontitis Diabetic Rats. *Eur. J. Dent.* 2020, 14, 404–409. [CrossRef] [PubMed]

40. Vezzani, G.; Iezzi, M.; Rizzato, A.; Quartsesan, S.; Mangar, D.; Camporesi, E.M.; Paganini, M.; Bosco, G. Effects of hyperbaric oxygen exposure on mobilization of endothelial progenitor cells in healthy volunteers. *Acta Med. Mediterr.* 2017, 33, 801–805.

41. Adamopoulos, I.E. Inflammation in bone physiology and pathology. *Curr. Opin. Rheumatol.* 2018, 30, 59–64. [CrossRef]